Evaluation of Drug Activity in Women With Breast Cancer and no Previous Herceptin Treatment

• Status: Terminated
• Trial end date: 2013-05-01
• Target enrollment: 0
• Participant gender: Female

Summary

To compare the activity of AZD8931 against placebo on the cell markers in cancer tumours

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca

Criteria

Inclusion Criteria:

• Females aged 18 or older Early stage breast cancer and planned surgery

• Ineligible for Trastuzumab (Herceptin) treatment as per local guidelines

• World health Organisation performance status of 0 to 1 Tumour size amenable to obtaining adequate biopsies pre dosing.

Exclusion Criteria:

• Eligible for Trastuzumab (Herceptin) Treatment Known sensitivity to AZD8931, its excipients or drugs in its class;

• Including oral tyrosine kinase inhibitors History of eye conditions e.g. previous injury within 3 months or clinically significant eye disease

• Concurrent malignancy Unable to discontinue medication or herbal supplement known to inhibit CYP3A4 or CYP2D6